Spyre Therapeutics (SYRE) Equity Ratio (2016 - 2025)
Spyre Therapeutics (SYRE) has disclosed Equity Ratio for 11 consecutive years, with 0.92 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio rose 8.06% year-over-year to 0.92, compared with a TTM value of 0.92 through Dec 2025, up 8.06%, and an annual FY2025 reading of 0.92, up 8.06% over the prior year.
- Equity Ratio was 0.92 for Q4 2025 at Spyre Therapeutics, up from 0.9 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.92 in Q4 2025 and bottomed at 1.18 in Q3 2023.
- Average Equity Ratio over 5 years is 0.58, with a median of 0.77 recorded in 2024.
- The sharpest move saw Equity Ratio crashed 260.48% in 2023, then skyrocketed 200.83% in 2024.
- Year by year, Equity Ratio stood at 0.76 in 2021, then fell by 7.4% to 0.71 in 2022, then dropped by 23.87% to 0.54 in 2023, then skyrocketed by 58.09% to 0.85 in 2024, then increased by 8.06% to 0.92 in 2025.
- Business Quant data shows Equity Ratio for SYRE at 0.92 in Q4 2025, 0.9 in Q3 2025, and 0.85 in Q2 2025.